Biosite Triage Cardio ProfilER
This article was originally published in The Gray Sheet
Executive Summary
Full-scale launch begins for chest pain diagnostic, offering quantitative creatinine kinase, myoglobin, troponin I and b-type natriuretic peptide measurements within 15 minutes. Cleared by FDA in March, the cardiovascular disease marker test addresses a $300 mil. potential market (1"The Gray Sheet" April 21, 2003, p. 42)...